Overview

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Status:
RECRUITING
Trial end date:
2026-03-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
Phase:
PHASE2
Details
Lead Sponsor:
BioArctic AB
Collaborator:
Worldwide Clinical Trials